Fenwick Represents Aeglea BioTherapeutics in its $36 Million Follow-On Offering

Fenwick & West represented Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, in its underwritten public offering of 4,500,000 shares of common stock at a price of $8.00 per share, with expected gross proceeds to Aeglea of $36 million. As part of the offering, Aeglea granted underwriters a 30-day option to purchase up to 675,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions.

Evercore Group L.L.C. and BMO Capital Markets Corp. acted as joint book-running managers. JonesTrading Institutional Services LLC acted as lead manager.

The Fenwick transaction team included corporate partners Robert Freedman and Effie Toshav and associates Amanda Rose, Can Sun and Derrick Chapman.